Inflammasome Therapeutics Reports Positive 3-Month Data for K8 in Geographic Atrophy Inflammasome Therapeutics, a clinical-stage biotech company at the forefront of developing dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative…
Neurodegenerative Disease Imaging and Biomarkers: Enigma and UW-Madison Partner Enigma Biomedical USA, Inc. (Enigma) and the University of Wisconsin–Madison (UW–Madison) have announced a new partnership aimed at advancing the development…
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, presented an exciting update to the investment community during the 43rd annual J.P. Morgan Healthcare Conference. In addition to…
Alnylam Reports Q4 and Full Year 2024 Revenue and 2025 Guidance Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNA interference (RNAi) therapeutics, today announced preliminary global net product revenues…
Gilead and LEO Pharma Partner on Oral STAT6 Program Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today revealed a strategic partnership aimed at fast-tracking the development and commercialization of…
Compass Pathways Sets Price for Underwritten Offering Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on accelerating access to evidence-based mental health innovations, has announced the pricing of an…
Pharma Innovator Frenelle Launches; CEO Missling Attends JPM 2025 Frenelle Pharma, a dynamic new player in the pharmaceutical industry, is proud to announce its official launch. The company is leveraging…
Highlights of FORE Biotherapeutics’ Pipeline Achievements and 2025 Strategic Objectives Highlights of FORE Biotherapeutics’ Pipeline Achievements and 2025 Strategic Objectives FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted…
Trial Success for MAR001 Phase 2a and New Acromegaly Program Unveiled by Marea Therapeutics Marea Therapeutics, a clinical-stage biotechnology company focused on developing next-generation treatments for cardio-endocrine diseases, shared important…
Pharmaceuticals Thetis Secures $8.975M for TP-317 Ulcerative Colitis Trial Thetis Pharmaceuticals LLC, a clinical-stage company focused on developing TP-317, a pioneering small molecule drug targeting the BLT1 receptor to treat…
Peanut Allergy Treatment Palforzia® Indication Expanded by European Commission for Toddlers Stallergenes Greer, a biopharmaceutical company specializing in allergen immunotherapy (AIT), has announced that the European Commission (EC) has granted…
Cardiometabolic Innovator Verdiva Bio Launches with $410M+ Series A to Advance Therapies Verdiva Bio Limited (“Verdiva”), a new clinical-stage biopharmaceutical company, announced its official launch today, aiming to innovate therapies…